Abstract
Background:
Biobanks have evolved from simple repositories into complex research infrastructures that require robust governance frameworks to ensure traceability, data integrity, and operational reliability. ISO 20387 provides internationally harmonized accreditation standards for biobanking; however, empirical evidence evaluating its organizational impact remains limited.
Methods:
We conducted a longitudinal observational study of a hospital-based biobank between 2019 and 2025. ISO 20387 accreditation obtained in 2022 was considered the structural intervention point in the analysis. Governance and quality indicators were evaluated across the sample lifecycle, including labeling error rate, metadata completeness, traceability completeness, nonconformity rate per 100 aliquots, on-time processing, and Corrective Action and Preventive Action (CAPA) closure time.
Results:
Operational activity expanded substantially during the study period, with annual aliquot production increasing from 2142 aliquots in 2019 to a peak of 7668 in 2022. Governance indicators improved progressively during the pre-accreditation phase and stabilized following accreditation. Metadata completeness increased from 74% to 86% before accreditation to 99%–100% afterward, while traceability completeness rose from 71%–73% to 98%–99%. Nonconformity rates declined from 2.03–2.43 per 100 aliquots before accreditation to 0.75–0.90 afterward. On-time processing improved from 87%–93% to 98.5%–99%, and median CAPA closure time decreased from 53–63 to 39–42 days.
Conclusions:
ISO 20387 accreditation was associated with structural stabilization of governance processes in a hospital-based biobank undergoing substantial operational expansion. These findings suggest that accreditation can act as a catalyst for governance maturation, helping biobanking infrastructures maintain operational control and quality performance while scaling activity.
Introduction
Biobanks have progressively evolved from simple sample repositories into complex research infrastructures supporting translational medicine, biomarker discovery, and precision health initiatives. Their scientific value depends not only on the availability of biological specimens but also on the reliability, traceability, and governance integrity of the entire sample lifecycle. Standardized collection, processing, storage, and controlled distribution of high-quality biospecimens are fundamental prerequisites for research reproducibility and regulatory accountability.
As biobanks expand in operational volume and protocol heterogeneity, governance robustness becomes a critical determinant of sustainability. Growth in activity introduces structural complexity, increasing exposure to risks related to data integrity, traceability gaps, workflow variability, and quality deviations. Within this framework, governance systems must evolve from adaptive operational management toward structured, system-level control mechanisms capable of ensuring stability under expansion.
The publication of ISO 20387 1 represented a significant step toward internationally harmonized governance requirements in biobanking. While earlier best-practice guidelines2–4 provide important operational and ethical guidance, ISO 20387 establishes a formal accreditation framework focused on competence, impartiality, risk management, and end-to-end traceability across the sample lifecycle. Its scope extends beyond procedural harmonization to the institutionalization of consistent operational control.
Accreditation may therefore represent not only regulatory alignment but also an organizational intervention capable of reshaping internal governance structures and operational practices.
Despite increasing international implementation, empirical evidence evaluating the longitudinal organizational impact of ISO 20387 accreditation—particularly in the context of expanding operational activity—remains limited. Understanding how governance systems behave under increasing operational pressure is essential for assessing the organizational impact of accreditation frameworks. Most published reports focus on accreditation preparation processes, whereas fewer studies examine whether accreditation is associated with sustained improvements in governance robustness, operational stability, and scalability over time.
Hospital-based biobanks provide a particularly relevant setting for such evaluation. Embedded within dynamic clinical environments, they must reconcile research demands, regulatory oversight, and operational constraints. Under these conditions, maintaining governance stability while accommodating increasing operational volume becomes essential for institutional credibility and long-term sustainability.
This study evaluates the performance trajectory of a hospital-based biobank over a 7-year period (2019–2025), examining whether ISO 20387 accreditation obtained in 2022 was associated with measurable changes in governance robustness, operational control, and quality system responsiveness. The objective was to determine whether accreditation corresponded to structural consolidation of governance rather than isolated procedural compliance. To the best of our knowledge, longitudinal empirical evaluations of governance performance before and after ISO 20387 accreditation remain scarce in the biobanking literature.
The study was conducted in a multispecialty biobank integrated within a hospital setting, supporting clinical and translational research within approved institutional protocols. During this period, encompassing both pre- and post-accreditation phases, the number of operators involved in biobanking activities increased from 3 to a peak of 8, reflecting progressive expansion of operational capacity. Activities included the handling of human biological specimens such as plasma, serum, peripheral blood mononuclear cells, tissue, and saliva. Preparation for ISO 20387 accreditation began in 2021 and involved progressive alignment of documentation, workflow standardization, and traceability procedures. Further details on the implementation and long-term maintenance of the ISO 20387 quality system in this setting have been described elsewhere. 5
Materials and Methods
Study setting
The study was conducted at a hospital-based biobank integrated within a tertiary academic medical center. Between 2019 and 2025, the biobank experienced progressive expansion in operational volume and research complexity. ISO 20387 accreditation was obtained in 2022 and introduced with structured governance criteria encompassing project activation, sample acceptance, processing standardization, metadata registration, traceability control, storage management, and documented release procedures.
Study design
A longitudinal observational design was applied from January 2019 to December 2025.
ISO 20387 accreditation obtained in 2022 was considered the structural intervention point. The observation period, therefore, included both pre-accreditation and post-accreditation phases, enabling evaluation of governance performance trajectories during operational expansion.
Governance performance was evaluated across the full sample lifecycle, including sample receipt, processing and aliquoting, metadata registration, traceability control, storage, and controlled release to authorized investigators.
To assess data integrity and workflow standardization, four indicators were examined:
Duplicate patient entry rate. Labeling error rate (per 100 processed aliquots). Metadata completeness rate. Traceability completeness rate (proportion of samples fully traceable from receipt to storage location).
A summary of the indicators, their definitions, and monitoring purposes is provided in Table 1.
Summary of Governance and Quality Indicators Evaluated Across the Sample Lifecycle
Indicators are presented with their definitions, data sources, and roles within the quality management system.
LIMS, laboratory information management system; QMS, quality management system.
Labeling errors included any discrepancy between physical labels and electronic records, incomplete field entries, formatting inconsistencies, or minor administrative deviations that did not compromise sample identification. No critical sample misidentification events occurred during the observation period.
Operational performance was assessed through the on-time processing rate, defined as the percentage of samples processed within the predefined maximum allowable interval from receipt, as specified in internal standard operating procedures.
Quality system stability was assessed using the nonconformity (NC) rate per 100 aliquots produced and the median Corrective Action and Preventive Action (CAPA) closure time.
Annual aliquot production was analyzed to contextualize governance evolution within increasing operational volume. Operational and quality data were routinely recorded in the biobank’s laboratory information management system and internal quality management records and were retrospectively extracted for analysis.
Statistical analysis
Descriptive statistics were calculated for all indicators. Given the observational design and the limited number of annual observations, emphasis was placed on longitudinal pattern analysis rather than inferential statistical testing. Performance trajectories were evaluated to identify temporal shifts in governance indicators in relation to the 2022 accreditation milestone and concurrent operational expansion.
Results
Between 2019 and 2025, the biobank experienced substantial operational expansion. Changes in operational volume and governance indicators are summarized in Figure 1. Annual aliquot production increased from 2142 aliquots in 2019 to a peak of 7668 aliquots in 2022 (Fig. 1A). Production remained elevated in the subsequent years, although moderate fluctuations were observed, including a decrease in 2025.
Longitudinal evolution of operational volume and governance indicators in relation to ISO 20387 accreditation.
Labeling error rates decreased progressively during the observation period. These indicators included minor labeling inconsistencies and administrative deviations that did not compromise sample identification or traceability. The rate declined from 36% in 2019 to 26% in 2021 and stabilized between 17% and 19.5% after accreditation.
Metadata completeness showed moderate variability during the early observation years (74%–86%) and increased sharply to near-complete levels following accreditation (99%–100%), where it remained consistently high (Fig. 1B).
Traceability completeness followed a similar trajectory. Values ranged between 71% and 73% prior to accreditation and increased markedly to 98%–99% after 2022 (Fig. 1B).
The NC rate declined substantially across the observation period (Fig. 1C). Between 2019 and 2021 values ranged from 2.03 to 2.43 per 100 aliquots, whereas after accreditation they consistently remained below 1 per 100 aliquots (0.75–0.90), despite the increase in operational volume.
Operational predictability improved concurrently. On-time processing increased from 87% to 93% before accreditation to stable levels between 98.5% and 99% afterward.
Median CAPA closure time decreased from 53 to 63 days during the earlier years of observation to between 39 and 42 days following accreditation.
Across all governance domains, a consistent pattern emerged: Progressive improvement before accreditation followed by sustained stabilization after 2022, occurring alongside substantial growth in operational volume.
Discussion
This longitudinal evaluation provides empirical insight into the evolution of governance processes in a hospital-based biobank undergoing substantial operational expansion. The findings indicate a trajectory of progressive improvement before accreditation followed by structural stabilization after its attainment.
Improvements in several governance indicators began during the preparatory phase and subsequently reached a stable plateau. This pattern is consistent with dynamics described during quality system implementation in laboratory and biobanking settings, in which preparatory activities—such as process alignment, documentation harmonization, and reinforcement of traceability procedures—gradually strengthen governance mechanisms before formal accreditation is achieved. 6 In line with these observations, our findings suggest that ISO 20387 accreditation may function less as the initial trigger of improvement and more as a structural consolidator of governance processes in biobanking infrastructures, reinforcing improvements that progressively emerged during the preparatory phase.
Across the observation period, governance indicators related to data integrity—such as metadata completeness and traceability—showed progressive improvement during the preparatory phase and reached near-complete levels following accreditation. Similarly, quality management indicators, including NC rates and CAPA closure time, demonstrated both reduction and stabilization after accreditation, suggesting increasing maturity of the quality management system.
Within the ISO 20387 framework, the concept of fitness-for-purpose represents a central element, ensuring that biological materials and associated data are suitable for their intended scientific use. While the present analysis focused on governance and operational performance indicators, nonconformities may also be considered in relation to their potential impact on sample fitness-for-purpose. Future studies could, therefore, explore how different types of nonconformities influence downstream processing, data quality, and research usability of biobank-derived materials.
It is important to note that the labeling error indicator included minor administrative deviations, such as formatting inconsistencies or incomplete metadata fields, which did not compromise sample identification or traceability. The inclusion of these low-severity deviations reflects a deliberately sensitive monitoring strategy within the quality management system, enabling early detection of workflow variability and supporting continuous process improvement. These governance improvements occurred concurrently with increasing operational demand.
After reaching a peak in 2022, operational activity showed moderate fluctuations, including a decline in 2025. Despite these variations in workload, governance indicators remained consistently stable at high performance levels. In many laboratory infrastructures, increasing workload tends to amplify process variability and increase the frequency of quality deviations. In contrast, the present findings suggest that once governance mechanisms were consolidated, governance performance became less sensitive to short-term variations in operational volume, supporting sustained operational stability during expansion.
From an organizational perspective, the longitudinal pattern observed in this study is consistent with dynamics of quality system implementation previously described in biobanking and laboratory settings,6,7 in which accreditation-oriented preparation progressively strengthens governance structures and operational control over time. The present findings extend these observations by showing a longitudinal pattern of progressive improvement followed by stabilization after accreditation despite continued operational growth.
Based on this trajectory, we suggest three sequential phases of governance evolution in biobanking: adaptive governance, governance consolidation, and stabilized governance under expansion, as illustrated in Figure 2.
Governance maturation in hospital-based biobanking. Conceptual model illustrating three sequential phases of governance evolution in biobanking: Adaptive governance, governance consolidation, and stabilized governance under expansion. The transition between phases is associated with implementation and attainment of ISO 20387 accreditation (2022), considered a key milestone in governance consolidation and operational standardization.
Phase 1: Adaptive governance
During early expansion phases, governance mechanisms remain functional but partially standardized, and performance indicators exhibit moderate variability as processes evolve alongside increasing activity.
Phase 2: Governance consolidation
Preparatory activities associated with accreditation introduce structural alignment across workflows, including risk mapping, documentation harmonization, and strengthened traceability systems.
Phase 3: Stabilized governance under expansion
Following accreditation, governance mechanisms become institutionalized, leading to reduced variability in performance indicators and improved responsiveness of the quality management system.
Within this framework, ISO 20387 accreditation can be interpreted as a structural factor that consolidates governance architecture and enables biobanks to maintain stability while scaling operational activity. These findings support the view of accreditation as an instrument of organizational maturation rather than merely a procedural compliance milestone, strengthening institutional governance and supporting scalable research infrastructures.
This capacity for stability under increasing operational complexity represents an important dimension of organizational resilience. Hospital-based biobanking infrastructures operate at the interface between clinical environments, research workflows, and regulatory oversight. In such settings, the ability to absorb increased workload while maintaining high levels of traceability and quality performance is essential for long-term sustainability.
Although causal inference cannot be definitively established within an observational design, the temporal convergence of improvements across multiple independent governance indicators strengthens the interpretation of accreditation as a structural consolidator of governance processes. The consistency of improvements across indicators related to data integrity, operational predictability, and quality management responsiveness suggests systemic organizational change rather than isolated procedural adjustments.
This study reflects the experience of a single hospital-based biobank and may, therefore, not be generalizable to larger population-based infrastructures or distributed biobank networks. In addition, the analysis was based on annual aggregated indicators and descriptive trend evaluation, which limits the possibility of formal statistical inference. Nevertheless, the extended longitudinal observation period and the coherence of governance improvements across multiple domains provide a robust empirical basis for interpreting the observed trajectory as an example of governance maturation in practice.
Overall, the present findings suggest that ISO 20387 accreditation may strengthen governance architecture and support scalable, resilient biobanking operations. These observations may provide a useful reference for other hospital-based biobanks undergoing accreditation or preparing to scale operational activity. Future multi-institutional analyses could further clarify whether similar governance maturation trajectories are observed across different types of biobanking infrastructures.
Research should also explore the downstream impact of governance and quality indicators—such as metadata completeness, method validation, sample quality control, and the evolution of CAPA types—on the reproducibility and scientific outcomes of research using biobank-derived samples.
Taken together, these findings support the interpretation of a progressive governance evolution in hospital-based biobanking infrastructures, in which process alignment during the preparatory phase is followed by sustained operational stabilization after accreditation. Within this trajectory, ISO 20387 accreditation appears to function as a key milestone supporting scalable and resilient biobanking operations.
Although these findings are consistent with this interpretation, the observational nature of the study does not allow causal inference. Furthermore, empirical evidence directly linking ISO 20387 accreditation to governance stabilization remains limited, highlighting the need for further studies to confirm this relationship across different biobanking settings.
Conclusions
The findings suggest that ISO 20387 accreditation may function not only as a compliance framework but also as a structural consolidator of governance within hospital-based biobanking. The observed combination of increasing operational volume and reduced variability in governance indicators indicates a trajectory of organizational maturation, supporting the role of accreditation in enabling stable and scalable biobanking operations over time.
Authors’ Contributions
A.Z. conceived the study, supervised the ISO 20387 accreditation process, and drafted the article. E.B. coordinated quality management activities and contributed to audit coordination. F.N. contributed to staff training and audit coordination. J.T. supported operational biobank activities. S.L. contributed to the intellectual revision of the article. All authors read and approved the final version of the article.
Footnotes
Ethics Statement
This study was based on a retrospective analysis of aggregated operational and quality management indicators routinely collected by the biobank. Ethics committee approval was not required because no human subjects were enrolled, no patient-level data were analyzed, and no biological specimens were used.
Disclosure Statement
The authors declare no conflicts of interest.
Funding Information
No funding was received for this article.